Clinical Trials Using Durvalumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Durvalumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 106
1 2 3 4 5 Next >

  • Durvalumab and Tremelimumab in Treating Patients with Recurrent Stage IV Lung Cancer (A Lung-MAP Treatment Trial)

    This phase II Lung-MAP trial studies how well durvalumab and tremelimumab works in treating patients with stage IV lung cancer that has come back after previous treatment. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 1066 locations

  • Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer (The Lung-MAP Screening Trial)

    This screening and multi-sub-study randomized phase II / III Lung-MAP trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid “Master Protocol” (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a “non-match” sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.
    Location: 915 locations

  • Durvalumab and Tremelimumab with or without High or Low-Dose Radiation Therapy in Treating Patients with Metastatic Colorectal or Non-small Cell Lung Cancer

    This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating patients with colorectal or non-small cell lung cancer that has spread to other parts of the body. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving durvalumab and tremelimumab with radiation therapy may work better in treating patients with colorectal or non-small cell lung cancer.
    Location: 33 locations

  • Comparing Photon Therapy To Proton Therapy To Treat Patients with Lung Cancer

    This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as photon or proton beam radiation therapy, may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as paclitaxel, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether proton chemoradiotherapy is more effective than photon chemoradiotherapy in treating non-small cell lung cancer.
    Location: 28 locations

  • A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

    This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in advanced hepatocellular carcinoma.
    Location: 14 locations

  • I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
    Location: 15 locations

  • Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

    This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC. The patients cannot be eligible for locoregional therapy.
    Location: 13 locations

  • Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent / Metastatic Head and Neck Cancer

    This is a Phase 1b / 2a, open-label, multi-center study to evaluate the safety and tolerability, anti-tumor activity, and immunogenicity of MEDI0457 (also known as INO 3112) a HPV DNA vaccine in combination with durvalumab (also known as MEDI4736) which is a human monoclonal antibody directed against PD-L1, which blocks the interaction of PD-L1 with PD-1 and CD80. An initial three to 12 patients (Safety Analysis Run-in patients) will be enrolled and assessed for safety before additional patients are enrolled. The initial safety analysis run-in patients along with an approximate total of 50 patients with human papilloma virus associated recurrent or metastatic head and neck squamous cell cancer will be enrolled in this study and evaluated also for anti-tumor efficacy to MEDI0457 in combination with durvalumab.
    Location: 11 locations

  • Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

    This is a multicenter, open-label, Phase 1 study to assess the safety and antitumor activity of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with myelodysplastic syndrome after treatment with hypomethylating agents
    Location: 10 locations

  • Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

    This multicentre, open-label, Phase 1b / 2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B
    Location: 10 locations

  • A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

    This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of Durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in Adult Subjects with selected advanced solid tumors and the combination of durvalumab and monalizumab (IPH2201) standard of care systemic therapy with or without biological agent and monalizumab (IPH2201) with biological agent administered to subjects with recurrent or metastatic colorectal cancer (CRC).
    Location: 10 locations

  • Iodine I-131, Recombinant Thyrotropin Alfa, and Durvalumab in Treating Patients with Recurrent or Metastatic Thyroid Cancer

    This pilot early phase I trial studies the side effects of iodine I-131, recombinant thyrotropin alfa, and durvalumab in treating patients with thyroid cancer that has come back after a period of improvement or that has spread to other parts of the body. Iodine I-131 is a radioactive form of iodine used to kill tumor cells and shrink tumors. Recombinant thyrotropin alfa may maximize the amount of iodine I-131 taken up by tumor cells. Monoclonal antibodies, such as durvalumab, may block tumor growth in different ways by targeting certain cells. Giving iodine I-131, recombinant thyrotropin alfa, and durvalumab may work better in treating patients with thyroid cancer.
    Location: 7 locations

  • Durvalumab and Tremelimumab in Treating Patients with Relapsed or Refractory Germ Cell Tumors

    This phase II trial studies how well durvalumab and tremelimumab work in treating patients with germ cell tumors that have returned after a period of improvement or do not respond to treatment. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 7 locations

  • Durvalumab, Tremelimumab, and Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Anaplastic Thyroid Cancer

    This pilot phase I trial studies how well durvalumab works in combination with tremelimumab and stereotactic body radiation therapy in treating patients with anaplastic thyroid cancer that has spread to other places in the body. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving durvalumab, tremelimumab, and stereotactic body radiation therapy may work best in treating patients with anaplastic thyroid cancer.
    Location: 7 locations

  • Durvalumab with or without Tremelimumab in Treating Patients with Recurrent or Persistent Endometrial Cancer

    This randomized phase II trial studies how well durvalumab with or without tremelimumab works in treating patients with endometrial cancer that has come back after a period of time or remains despite treatment. Monoclonal antibodies, such as durvalumab and tremelimumab, may block tumor growth in different ways by targeting certain cells.
    Location: 7 locations

  • AZD9291 in Combination With Ascending Doses of Novel Therapeutics

    The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer.
    Location: 8 locations

  • Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1 / PD-L1 Containing Therapy.

    This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1 / PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
    Location: 8 locations

  • Vaccine Therapy with or without Durvalumab in Treating Patients with Early Stage Triple Negative Breast Cancer

    This phase Ib trial studies the side effects of vaccine therapy with or without durvalumab in treating patients with early stage triple negative breast cancer. Vaccine therapy may stimulate the immune system. Monoclonal antibodies, such as durvalumab, may block a protein used by tumor cells which may help the immune system identify and catch tumor cells. Vaccine therapy and durvalumab may work together to help the immune system recognize triple negative breast cancer.
    Location: 6 locations

  • Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

    This study is a Phase 2, open-label, multicenter study evaluating adoptive cell therapy (ACT) with autologous TIL therapy (LN-145) in combination with Anti-PD-L1 inhibitor durvalumab.
    Location: 5 locations

  • A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed / Refractory B-cell Malignancies (PLATFORM)

    This is an open-label, multi-arm, multi-cohort, multi-center, Phase 1 / 2 study to determine the safety, tolerability, PK, efficacy and patient reported quality of life of JCAR017 in combination with various agents. The first combination, defined as Arm A, will evaluate JCAR017 in combination with durvalumab. The second combination, defined as Arm B, will evaluate JCAR017 in combination with CC-122.Within each arm, cohorts and subcohorts will test different doses and / or schedules of the combination agent(s). The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2).
    Location: 7 locations

  • Durvalumab, Chemotherapy, and Radiation Therapy before Surgery in Treating Patients with Esophageal or Gastroesophageal Junction Cancer

    This pilot phase Ib / II trial studies the side effects of durvalumab when given together with chemotherapy and radiation therapy in treating patients with esophageal or gastroesophageal junction cancer. Monoclonal antibodies, such as durvalumab, blocks a protein called PD-L1 and may help the immune system by blocking some of the processes that stop the immune system from working. Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, oxaliplatin, carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving durvalumab together with chemotherapy and radiation therapy before surgery may work better at treating patients with esophageal or gastroesophageal junction cancer.
    Location: 5 locations

  • A Phase 1 / 2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers

    This is an open-label, multicenter Phase 1 / 2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator polyICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers.
    Location: 5 locations

  • MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

    The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Subjects with Select Advanced Solid Tumors
    Location: 5 locations

  • MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study

    The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in subjects with metastatic pancreatic cancer.
    Location: 6 locations

  • Durvalumab and Tremelimumab in Treating Patients with Metastatic Urinary Tract Cancer

    This phase II trial studies how well durvalumab and tremelimumab work in treating patients with urinary tract cancer that has spread to other places in the body. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread.
    Location: 4 locations


1 2 3 4 5 Next >